Health

STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 22/10/2026, 13:51:24 UTC.

Briefings

STAT+ reports on telehealth companies marketing off-label GLP-1 prescriptions for alcohol use disorder, noting expert concerns about fragmented care. It also reports the U.S. Department of Treasury's proposed rule under the COINS Act requiring scrutiny of outbound U.S. licensing deals with Chinese biotech companies, citing concerns over China's ambitions and anti-pharma sentiment.

Key points

• Telehealth platforms are currently marketing off-label prescriptions of GLP-1 drugs to treat alcohol use disorder and other addictions.
• The U.S. Department of Treasury is proposing a rule under the COINS Act that would subject outbound U.S. licensing deals with Chinese biotech companies to additional regulatory scrutiny.

Context

STAT+ covers recent developments in addiction medicine and U.S. trade policy, specifically the emerging market for off-label GLP-1 prescriptions and the proposed Treasury rule on Chinese biotech investments.

Limitations

Evidence is limited to reported facts and expert commentary; no specific dates for the proposed Treasury rule are provided, and the article does not contain data on the scale of telehealth marketing or specific patient outcomes.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 22/10/2026, 13:52:05 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidzvymcrhdt2cqxjcogy5upqemgvajulkbgawhd4lbg6dto5wbdva